Warning Letter Roundup & Recap – Sept. 5, 2017
US FDA broke a six-week dry spell by finally posting a handful of device-related warning letters online this week, touching on problematic complaint handling practices, marketing of unapproved devices and a bevy of quality systems violations. All six letters were written by the agency's device center.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.